Collegium Pharmaceutical had its Relative Strength (RS) Rating upgraded from 68 to 73 Monday — a welcome improvement, but still below the 80 or better score you look for.
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks compares to the rest of the market.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 as they launch their biggest runs. See if Collegium Pharmaceutical can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Collegium Pharmaceutical is not currently near a potential buy zone. See if the stock goes on to build a base that could ignite a new run.
The company reported 10% earnings growth last quarter, while sales growth came in at 0%.
The company earns the No. 3 rank among its peers in the Medical-Generic Drugs industry group. Teva Pharmaceutical ADR is the top-ranked stock within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
